BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY

eISSN: 1179-9889pISSN: 1179-9889
JournalOpen Access

Journal formatting to fit the target journal guidelines

Experts ensure all elements of your paper match journal formatting guidelines to improve publication success rate!

Journal Specifications

Indexed in the following public directories

  • Web of Science
  • DOAJ
Overview
  • Publisher
    DOVE MEDICAL PRESS LTD
  • Language
    English
  • Frequency
    Continuous publication
  • Article Processing Charges
    USD 2390
  • Publication Time
    16
  • Editorial Review Process
    Anonymous peer review
General Details
Publication Details
Editorial Review Detail
Information for authors
View less

Year-wise Publication

FAQs

Since when has BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY been publishing? Faqs

The BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY has been publishing since 2011 till date.

How frequently is the BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY published? Faqs

BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY is published Continuous publication.

Who is the publisher of BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY? Faqs

The publisher of BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY is DOVE MEDICAL PRESS LTD.

How can I view the journal metrics of BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY on editage? Faqs

For the BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY metrics, please refer to the section above on the page.

What is the eISSN and pISSN number of BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY? Faqs

The eISSN number is 1179-9889 and pISSN number is 1179-9889 for BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY.

Why is it important to find the right journal for my research? Faqs

Choosing the right journal ensures that your research reaches the most relevant audience, thereby maximizing its scholarly impact and contribution to the field.

Can the choice of journal affect my academic career? Faqs

Absolutely. Publishing in reputable journals can enhance your academic profile, making you more competitive for grants, tenure, and other professional opportunities.

Is it advisable to target high-impact journals only? Faqs

While high-impact journals offer greater visibility, they are often highly competitive. It's essential to balance the journal's impact factor with the likelihood of your work being accepted.